Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Gary A. Lyons sold 10,000 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $72.92, for a total transaction of $729,200.00. Following the transaction, the director now directly owns 272,066 shares of the company’s stock, valued at $19,839,052.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) traded down $1.00 during trading hours on Wednesday, hitting $70.98. 603,900 shares of the stock were exchanged, compared to its average volume of 1,106,568. Neurocrine Biosciences, Inc. has a 12 month low of $37.35 and a 12 month high of $75.98. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.36. The business had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same quarter in the previous year, the firm earned ($0.43) earnings per share. equities analysts forecast that Neurocrine Biosciences, Inc. will post -1.74 earnings per share for the current year.
A number of research analysts have issued reports on NBIX shares. Robert W. Baird reissued a “buy” rating and set a $84.00 target price on shares of Neurocrine Biosciences in a research note on Friday, November 3rd. Piper Jaffray Companies reissued a “buy” rating and set a $76.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, October 25th. Jefferies Group reissued a “buy” rating and set a $69.00 target price (up from $66.00) on shares of Neurocrine Biosciences in a research note on Tuesday, October 3rd. Deutsche Bank reissued a “buy” rating and set a $79.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Finally, BMO Capital Markets reissued an “outperform” rating and set a $84.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 5th. One equities research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $78.88.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/12/06/neurocrine-biosciences-inc-nbix-director-gary-a-lyons-sells-10000-shares-of-stock.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.